

To,
MSD - Non Continuous Markets Group
National Stock Exchange of India Limited
Mumbai.

Date: June 17, 2026

Dear Sir,

Sub.: Issue details for Anchor allocations of IPO of Avience Biomedicals Limited

The Board of Directors of the company at its meeting held on 17-06-2026 in consultation with the Book Running Lead Managers to the Issue, have finalized allocation of 4,09,800, to Anchor Investors at Anchor Investor issue price Rs. 208 per share in the following manner:

SR NO	Name of Anchor Investor	No. of Equity Shares Allocated	No of Equity Shares allocated as a % of Anchor Investor Portion	Bid Price (Rs. per Equity Share)	Total Amount Allocation (Rs.)
1.	Sanshi Fund-I	1,44,600	35.29%	208	3,00,76,800
2.	Meru Investment Fund PCC- Cell I	1,20,600	29.43%	208	2,50,84,800
3.	Fortune Hands Growth Fund Scheme I	96,000	23.43%	208	1,99,68,000
4.	Shine Star Build Cap Pvt Ltd	48,600	11.86%	208	1,01,08,800
	Total	4,09,800	100.00%		8,52,38,400

Out of the total allocation (no of Equity Shares) to the Anchor investor, (no of Equity Shares) (i.e. % of the total allocation to Anchor Investors) are allocated to domestic mutual fund (no of Mutual Funds) through a total of (no of schemes), and (i.e. % of the total allocation to Anchor Investors) are allocated to Life insurance companies and pension fund, details of which are provided in the table below:- No shares are allocated to Domestic Mutual Fund category, Life insurance companies and pension fund

SR NO	Name of Scheme	No. of Equity Shares Allocated	No of Equity Shares allocated as a % of Anchor Investor Portion	Bid Price (Rs. per Equity Share)	Total Amount Allocation (Rs.)
1.	Nil	Nil	Nil	Nil	Nil
	Total				

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, in case the Offer Price discovered through book building process is

For Avience Biomedicals Limited


Managing Director

higher than the Anchor investor Allocation Price, Anchor investors will be required to pay the difference by the Anchor investor Pay-in Date as specified in the revised CAN.

Further, as per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, from time to time, we shall abide by Schedule XIII, Part A, Clause 10 and all relevant sub-clauses.

Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Red Herring Prospectus dated June 12, 2026 filed with the Registrar of Companies, Delhi at 4th Floor, IFCI Tower, 61, Nehru Place, New Delhi – 110019 to be read along with price band advertisement dated June 15, 2026.

We request you to make the above information public by disclosing the same on your website.

Thanking You

For Avience Biomedicals Limited
For Avience Biomedicals Limited

Dharam Deo Choudhary
Managing Director
DIN: 02804625

Managing Director

Place- New Delhi

Anchor Investor	No. of Equity Shares allocated as a % of Shares	Bid Price (Rs. per Equity Share)	Total Amount Allocation (Rs.)
		208	3,52,38,400
		208	3,52,38,400
	21.83%	208	1,99,68,000
	11.81%	208	1,01,02,800
	100.00%		8,52,38,400

Out of the total allocation (no. of Equity Shares) to the Anchor investor, (no. of Equity Shares) (11.81% of the total allocation to Anchor Investors) are allocated to domestic mutual fund (no. of Mutual Funds) through a trust (no. of trustees), and (11.81% of the total allocation to Anchor Investors) are allocated to Life insurance companies and pension fund, details of which are provided in the table below. No shares are allocated to Domestic Mutual Fund category, Life insurance companies and pension fund.

Sr. No.	Name of Scheme	No. of Equity Shares Allocated	No. of Equity Shares allocated as a % of Anchor Investor Portfolio	Bid Price (Rs. per Equity Share)	Total Amount Allocation (Rs.)
				Nil	Nil
				Nil	Nil

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, in case the Offer Price discovered through book building process is

For Avience Biomedicals Limited

Managing Director